Lenvima (Lenvatinib)

Lenvatinib blocks multiple receptor tyrosine kinases such as VEGFR, FGFR, PDGFRα, RET and KIT. By inhibiting these pathways, it reduces tumor blood‑vessel formation and interferes with signals that drive cancer cell growth, resulting in anti‑angiogenic and antiproliferative effects.

The prescribed dose of Lenvima is individualized by the treating oncologist based on the specific indication, patient weight, renal function and tolerability. Only a qualified healthcare professional can determine the appropriate regimen.

Safety data for lenvatinib in pregnancy and lactation are limited, and the drug may cause fetal harm. It is generally contraindicated in pregnant women, and breastfeeding is not recommended while on therapy.

To request Lenvima, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lenvima uniquely targets a broad panel of kinases including VEGFR, FGFR, PDGFRα, RET and KIT, offering a wider anti‑angiogenic profile than some single‑target TKIs. This multi‑target approach can provide clinical benefit in cancers where multiple pathways drive disease, but the safety profile also requires careful monitoring.

Lenvima tablets should be stored at ambient temperature below 25 °C, protected from moisture and light, and kept in the original packaging until use. Do not store in a bathroom or near heat sources.

Lenvima is taken orally as a tablet, usually once daily on an empty stomach, unless the prescriber advises otherwise. Patients should swallow the tablet whole with water and follow any specific instructions regarding food or timing provided by their healthcare professional.

Serious risks include severe hypertension, hepatic failure, arterial thromboembolic events, gastrointestinal perforation or fistula formation, and significant bleeding. Patients should be monitored closely for these events, and any concerning symptoms should prompt immediate medical evaluation.

Lenvima is contraindicated in patients with known hypersensitivity to lenvatinib or any of its excipients. It should also be avoided in pregnant women and used with caution in individuals with uncontrolled hypertension, severe liver impairment, or those taking interacting medications that cannot be managed.